Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. Animal Model: Mice harbouring OPM2 tumours[2] Dosage: 4 mg/kg Administration: IP, twice weekly for 4 doses Result: Signifcantly improves survival compared to vehicle.
In Vitro
Belantamab mafodotin binds to human BCMA protein with a Kd of 1 nM[2]. Belantamab mafodotin induces G2/M arrest in multiple myeloma cells in a dose and time dependent manner[2]. Belantamab mafodotin signifcantly promotes phagocytosis of multiple myeloma cells by human macrophages derived from macrophage colony-stimulating factor-stimulated monocytes[2].
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.
[2]. Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
